Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia (FETCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04362046
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : October 20, 2021
Sponsor:
Collaborator:
University of British Columbia
Information provided by (Responsible Party):
Mark Carey, Vancouver Coastal Health Research Institute

Brief Summary:
This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy. Patients in this study wish to preserve fertility.

Condition or disease Intervention/treatment Phase
Endometrial Hyperplasia Endometrial Cancer Gynecologic Cancer Procedure: Hysteroscopic uterine resection Not Applicable

Detailed Description:
Endometrial cancer (EC) is the most common gynecological cancer among Canadian women. This cancer often arises from a precursor lesion called atypical endometrial hyperplasia (AH). Hysterectomy is the most effective treatment for EC and AH. It is well recognized that EC may be diagnosed in younger women of child-bearing age. The diagnosis of EC or AH in these younger women is devastating as a hysterectomy is frequently required. Though some of these women respond to high-dose progestin treatment, the failure rate is high (60%), necessitating surgery. Recent case series show that some women with AH and early EC can be treated by resecting the precursor lesion of the early cancerous area in the uterus by hysteroscopy without the need for hysterectomy. The fertility-sparing approach is outlined in this research protocol.This is a multidisciplinary research project with input from gynaecologic oncology, general gynaecology, reproductive endocrinology and infertility, and pathology. Our hypothesis is that hysteroscopic resection (HR) is a safe and effective treatment for AH or EC in women who want to preserve their fertility and have not been successfully treated using progestin therapy. Patients will be closely monitored to ensure that this is a safe and effective treatment option.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fertility Preservation Using Endomyometrial Resection for Atypical Hyperplasia and Low Grade, Stage 1A, Endometrial Cancer
Actual Study Start Date : November 15, 2020
Estimated Primary Completion Date : July 2028
Estimated Study Completion Date : July 2028

Arm Intervention/treatment
Experimental: Hysteroscopic uterine resection
This is a prospective single-arm surgical intervention trial.
Procedure: Hysteroscopic uterine resection

Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.

HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications.





Primary Outcome Measures :
  1. Conception rate of women attempting pregnancy [ Time Frame: 3 years post-resection ]
    live births / women attempting pregnancy

  2. Overall conception rate [ Time Frame: 3 years post-resection ]
    live births / all women participating in study, including those who failed hysteroscopic resection and have a hysterectomy

  3. Local disease control rate (short-term failure of hysteroscopic resection) [ Time Frame: 3 months post-resection ]
    Patients with persisting atypical hyperplasia or Grade I endometrial cancer / patients treated with hysteroscopic resection

  4. Distant disease control rate (long-term failure of hysteroscopic resection) [ Time Frame: 3 years post-resection ]
    patients developing distant recurrence / patients treated with hysteroscopic resection


Secondary Outcome Measures :
  1. Complications/side-effects [ Time Frame: 3 years post-resection ]
    The investigators will tabulate complications/side-effects of the procedure such as the rate of uterine perforation, uterine adhesion, procedure infection, and others.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   This study being conducted on women who have Grade 1 endometrial cancer or atypical endometrial hyperplasia
Accepts Healthy Volunteers:   No
Criteria

All candidates for this protocol must have an adequate trial of anti-hormone therapy prior to hysteroscopic resection. In cases of EC, the minimum trial is 6 months of high-dose progestin. In cases of AH, being that this is a benign condition (pre-malignant), patients may not require a full 6 months of anti-hormone therapy. All patients must have a pre-HR hysteroscopic evaluation to confirm that they are suitable candidates for this study. Patients being considered for the experimental intervention (hysteroscopic resection) will be reviewed and discussed by the study committee in order to ensure that the following criterion are met in order to proceed with the surgical resection:

Inclusion criteria:

  • Age less than 40 years
  • Pathologist confirmed biopsy evidence of one of the following:

    1. Grade I endometrial endometrioid adrenocarcinoma (EC) with less than 1/3 of the endometrial surface involved.
    2. Atypical endometrial hyperplasia (AH)
  • MRI demonstrating less than 1/3 myometrial invasion if the patient has EC
  • Absence of significant surgical co-morbidities e.g. pulmonary hypertension, significant cardiac valvular disease, or contraindication to surgery.
  • Desire to preserve fertility
  • Reasonable chance to conceive based on consultation with an infertility specialist
  • Adequate dose and duration of progesterone therapy prior to enrolment:
  • Adequate dose:

    1. Medroxyprogesterone acetate (Provera; 200mg/day)
    2. Megestrol acetate (Megace; 160mg/day)
  • Adequate duration: 6 months
  • Failure of progestin therapy defined as:

    1. Unsuccessful eradication of hyperplasia or cancer in the uterus
    2. Intolerance to the side effects
  • Signed informed consent

Exclusion criteria:

  • Age 40 years and over
  • Grade 2 or 3 endometrioid endometrial adenocarcinoma or non-endometrioid pathology
  • Greater than 1/3 involvement of the endometrial surface in patients with Grade I EC
  • Women who are not able to provide informed consent
  • Women without pathologic confirmation of low-grade endometrioid carcinoma or AH
  • Myometrial invasion on MRI greater than 1/3 total myometrial thickness.
  • MRI evidence of ovarian or adnexal involvement
  • The diagnosis of another cancer or medical condition that would interfere with the assessment of the hysteroscopic surgery success rates.
  • Significant underlying fertility impairment that would significantly interfere with the success rate of HR

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362046


Contacts
Layout table for location contacts
Contact: Neeraj Mehra, MD 604-875-5508 neeraj.mehra@ubc.ca

Locations
Layout table for location information
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Janice Kwon, MD    604-875-4268    janice.kwon@vch.ca   
Principal Investigator: Neeraj Mehra, MD         
Sponsors and Collaborators
Vancouver Coastal Health Research Institute
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Mark Carey, MD Vancouver Coastal Health
Layout table for additonal information
Responsible Party: Mark Carey, Clinical Professor, Vancouver Coastal Health Research Institute
ClinicalTrials.gov Identifier: NCT04362046    
Other Study ID Numbers: H17-00780
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The information in database/registry is anonymized. Inadvertent disclosure of the data poses no risk to patients.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mark Carey, Vancouver Coastal Health Research Institute:
Fertility preservation
Hysteroscopic uterine resection
High-dose progesterone
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Endometrial Hyperplasia
Hyperplasia
Pathologic Processes
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases